BINV Stock Overview
A clinical-stage company, discovers, researches, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
BioInvent International AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 23.55 |
| 52 Week High | SEK 50.80 |
| 52 Week Low | SEK 15.42 |
| Beta | 0.37 |
| 1 Month Change | -18.51% |
| 3 Month Change | -50.42% |
| 1 Year Change | 45.37% |
| 3 Year Change | -31.54% |
| 5 Year Change | -33.10% |
| Change since IPO | -98.22% |
Recent News & Updates
Recent updates
Is BioInvent International (STO:BINV) In A Good Position To Invest In Growth?
Aug 16
We Think BioInvent International (STO:BINV) Needs To Drive Business Growth Carefully
Apr 09Companies Like BioInvent International (STO:BINV) Are In A Position To Invest In Growth
Sep 01Earnings Working Against BioInvent International AB (publ)'s (STO:BINV) Share Price Following 29% Dive
Jun 02Analysts Are Betting On BioInvent International AB (publ) (STO:BINV) With A Big Upgrade This Week
Feb 25We're Hopeful That BioInvent International (STO:BINV) Will Use Its Cash Wisely
Sep 28Time To Worry? Analysts Just Downgraded Their BioInvent International AB (publ) (STO:BINV) Outlook
Aug 31Shareholder Returns
| BINV | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -7.1% | -3.9% | 2.6% |
| 1Y | 45.4% | 11.5% | 13.5% |
Return vs Industry: BINV exceeded the Swedish Biotechs industry which returned 11.5% over the past year.
Return vs Market: BINV exceeded the Swedish Market which returned 13.5% over the past year.
Price Volatility
| BINV volatility | |
|---|---|
| BINV Average Weekly Movement | 6.6% |
| Biotechs Industry Average Movement | 8.6% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 12.0% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: BINV has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: BINV's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 115 | Martin Welschof | www.bioinvent.com |
BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. Its drug candidates are BI-1808 is in phase 2 clinical trial and BI-1910 in phase 1 clinical trial for solid tumors targeting Tumor necrosis factor receptor-2 (TNFR2); BI-1206/rituximab in phase 2 clinical trial for the treatment of non-Hodgkin’s lymphoma; BI-1206/pembrolizumab and BI-1607/trastuzumab in phase 1 clinical trial to treat solid tumors targeting FCYRIIB; and BT-001 in phase 1 clinical trial for the treatment of solid tumors targeting Cytotoxic T lymphocyte-associated protein-4. The company has a partnership and collaboration with Transgene to develop BT-001 oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck to evaluate BI-1206, BI-1808, and BT-001 in combination with Keytruda; and licensing agreement with CASI pharmaceuticals for BI-1206.
BioInvent International AB (publ) Fundamentals Summary
| BINV fundamental statistics | |
|---|---|
| Market cap | SEK 1.55b |
| Earnings (TTM) | -SEK 409.65m |
| Revenue (TTM) | SEK 38.64m |
40.1x
P/S Ratio-3.8x
P/E RatioIs BINV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BINV income statement (TTM) | |
|---|---|
| Revenue | SEK 38.64m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 38.64m |
| Other Expenses | SEK 448.29m |
| Earnings | -SEK 409.65m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 27, 2025
| Earnings per share (EPS) | -6.23 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,060.29% |
| Debt/Equity Ratio | 0% |
How did BINV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 06:22 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioInvent International AB (publ) is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Morten Larsen | ABG Sundal Collier |
| Camilla Oxhamre | Carnegie Investment Bank AB |
| Mattias Häggblom | Danske Bank |